Cancer drug resistance: an evolving paradigm
The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10,11].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [10]
In the citing paper
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistance across KRAS mutant cancers.57,58”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Self-citationNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Cited by
Items 801–900 of 1,016
Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors
Hahne, J. C., & Valeri, N. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00226 · Cited by 75
Chen, X., Qiu, Y., Owh, C., Loh, X. J., & Wu, Y. (2016) · Nanoscale · doi:10.1039/c6nr08055c · Cited by 73
Imaging techniques to study drug transporter function in vivo
Tournier, N., Stieger, B., & Langer, O. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.006 · Cited by 79
Synchronous Chemoradiation Nanovesicles by X‐Ray Triggered Cascade of Drug Release
Zhou, Z., Chan, A., Wang, Z., Huang, X., Yu, G., Jacobson, O., Wang, S., Liu, Y., Shan, L., Dai, Y., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802351 · Cited by 75
Czarnomysy, R., Surażyński, A., Muszyńska, A., Gornowicz, A., Bielawska, A., & Bielawski, K. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1471687 · Cited by 72
“Although most conventional chemotherapies seem to result in success initially, they cannot eliminate the malignant clone totally and the disease relapses due to this therapy-resistant subpopulation 2,3 .”
Lin, F., Wen, D., Wang, X., & Mahato, R. I. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.036 · Cited by 73
“Development of chemoresistance poses a serious problem in cancer chemotherapy [1,2].”
Backgroundc-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors
Strippoli, A., Cocomazzi, A., Basso, M., Cenci, T., Ricci, R., Pierconti, F., Cassano, A., Fiorentino, V., Barone, C. A., Bria, E., et al. (2020) · Cancers · doi:10.3390/cancers12030638 · Cited by 77
Curcumin effect on cancer cells' multidrug resistance: An update
Keyvani‐Ghamsari, S., Khorsandi, K., & Gul, A. (2020) · Phytotherapy Research · doi:10.1002/ptr.6703 · Cited by 77
Necroptosis in cancer: An angel or a demon?
Wang, T., Jin, Y., Yang, W., Zhang, L., Jin, X., Liu, X., He, Y., & Li, X. (2017) · Tumor Biology · doi:10.1177/1010428317711539 · Cited by 77
Tumor-targeted drug delivery and sensitization by MMP2-responsive polymeric micelles
Yao, Q., Liu, Y., Kou, L., Tu, Y., Tang, X., & Zhu, L. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.03.012 · Cited by 74
Rui, L., Xue, Y., Wang, Y., Gao, Y., & Zhang, W. (2017) · Chemical Communications · doi:10.1039/c7cc00950j · Cited by 71
Jena, B. C., & Mandal, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188488 · Cited by 81
Normanno, N., Apostolidis, K., Lorenzo, F. D., Beer, P. A., Henderson, R., Sullivan, R. J., Biankin, A. V., Horgan, D., & Lawler, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.002 · Cited by 83
Drug and apoptosis resistance in cancer stem cells (CSCs): A puzzle with many pieces
Safa, A. R. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.20 · Cited by 84
NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
Yang, Y., Zhou, W. H., Xia, J., Gu, Z., Wendlandt, E. B., Zhan, X., Janz, S., Tricot, G. J. K., & Zhan, F. (2014) · Oncotarget · doi:10.18632/oncotarget.2388 · Cited by 77
“Overcoming drugresistant myeloma in the clinic is a serious challenge that requires new approaches based on results from highthroughput proteomic and genetic analysis tools, such as global gene expression profiling (GEP), RNA sequencing and whole-exome or whole-genome sequencing, which must be combined with sophistica…”
BackgroundEmerging therapeutic targets in metastatic progression: A focus on breast cancer
Li, Z., & Kang, Y. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.003 · Cited by 75
“This could be due to secondary mutations that abrogate contact points for drug binding, and/or activation of alternative compensatory signaling mechanisms (Garraway and Jänne, 2012; Holohan et al., 2013).”
BackgroundAntivascular and antitumor properties of the tubulin-binding chalcone TUB091
Canela, M., Noppen, S., Bueno, O., Prota, A. E., Bargsten, K., Sáez-Calvo, G., Jimeno, M. L., Benkheil, M., Ribatti, D., Velázquez, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9527 · Cited by 78
“Resistance and lack of efficacy associated with current antineoplastic treatments demand the design of novel anticancer drugs [2].”
BackgroundWang, X., Liow, S. S., Wu, Q., Li, C., Owh, C., Li, Z., Loh, X. J., & Wu, Y. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700186 · Cited by 73
Inhibition of cancer stem cell like cells by a synthetic retinoid
Chen, J., Cao, X., An, Q., Zhang, Y., Li, K., Yao, W., Shi, F., Pan, Y., Jia, Q., Zhou, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03877-7 · Cited by 72
ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells
Xu, Y., Gao, W., Zhang, Y., Wu, S., Liu, Y., Deng, X., Xie, L., Yang, J., Yu, H., Su, J., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4476 · Cited by 81
“uptake, repair of DNA adducts, and evasion of apoptosis (3,4).”
BackgroundDurinikova, E., Kozovská, Z., Poturnajova, M., Plavá, J., Čierna, Z., Bábelová, A., Bohovic, R., Schmidtova, S., Tomáš, M., Kučerová, L., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4758-y · Cited by 77
Xiang, S., Dauchy, R. T., Hoffman, A. E., Pointer, D. T., Frasch, T., Blask, D. E., & Hill, S. M. (2019) · Journal of Pineal Research · doi:10.1111/jpi.12586 · Cited by 72
Fang, Z., Pan, S., Gao, P., Sheng, H., Li, L., Shi, L., Zhang, Y., & Cai, X. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118841 · Cited by 74
Cao, R., Sun, W. C., Zhang, Z., Li, X., Du, J., Fan, J., & Peng, X. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.06.031 · Cited by 70
Wu, H., Liu, Y.-E., Hsu, K., Wang, Y., Chan, Y.-C., Chen, Y., & Chen, D. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x20500603 · Cited by 70
Kim, J., Shim, M. K., Yang, S., Moon, Y., Song, S., Choi, J., Kim, J., & Kim, K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.065 · Cited by 73
Pun, N. T., & Jeong, C. (2021) · Pharmaceuticals · doi:10.3390/ph14050470 · Cited by 82
“In contrast, acquired resistance develops during or after treatment of tumors that are sensitive initially but can develop mutations later or after adaptive responses such as mutation, drug efflux, drug activation/inactivation, and alteration of the drug target [4,22].”
BackgroundArif, M., Ahmad, S., Ge, F., Kabir, M., Khan, Y. D., Yu, D., & Thafar, M. A. (2021) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2021.104458 · Cited by 73
Hydroxyethyl starch-folic acid conjugates stabilized theranostic nanoparticles for cancer therapy
Wang, C., Wang, Q., Wang, H., Li, Z., Chen, J., Zhang, Z., Zeng, H., Yu, X., Yang, X., Yang, X., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.059 · Cited by 73
Chronic hepatitis B: A wave of new therapies on the horizon
Block, T. M., Rawat, S., & Brosgart, C. L. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.014 · Cited by 74
Carson, R., Çeltikçi, B., Fenning, C., Javadi, A., Crawford, N., Pérez–Carbonell, L., Lawler, M., Longley, D. B., Johnston, P. G., & Schaeybroeck, S. V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2701 · Cited by 77
“The importance of c-MET as mediator of acute resistance to MEK1/2 inhibitors was demonstrated in vivo, where cotreatment of BRAFMT colorectal cancer xenografts with crizotinib blocked AZD6244-induced STAT3 activation and resulted in supra-additive reductions in tumor growth and marked induction of apoptosis (24).”
BackgroundSelf-citationRodrigues, T., Sieglitz, F., & Bernardes, G. J. L. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00916b · Cited by 71
Attacking the supply wagons to starve cancer cells to death
Selwan, E. M., Finicle, B. T., Kim, S. M., & Edinger, A. L. (2016) · FEBS Letters · doi:10.1002/1873-3468.12121 · Cited by 69
“In summary, metabolic inhibitors suffer from the same limitations as therapies targeting oncogenic signal transduction cascades [10–13].”
BackgroundMMP2-Sensitive PEG–Lipid Copolymers: A New Type of Tumor-Targeted P-Glycoprotein Inhibitor
Dai, Z., Yao, Q., & Zhu, L. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b03064 · Cited by 73
Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer
Goldman, A., Kulkarni, A., Kohandel, M., Pandey, P., Rao, P., Natarajan, S. K., Sabbisetti, V., & Sengupta, S. (2016) · ACS Nano · doi:10.1021/acsnano.6b00320 · Cited by 70
Fan, J., Zheng, D., Rong, L., Zhu, J., Hong, S., Li, C., Xu, Z., Cheng, S., & Zhang, X. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.06.007 · Cited by 71
“As it is well known, with the effect of chemotherapeutic agents, cancer cells would undergo adaptive changes and update their drug resistance ability, which make chemotherapeutic agents less effective [12].”
Altıntop, M. D., Ciftci, H. I., Radwan, M. O., Sever, B., Kaplancıklı, Z. A., Ali, T. F. S., Koga, R., Fujita, M., Otsuka, M., & Özdemır, A. (2017) · Molecules · doi:10.3390/molecules23010059 · Cited by 78
miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells
Meng, X., & Fu, R. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s159093 · Cited by 70
“21 In a previous study, miRNAs have been stratified into mediators that regulate the response of cancer cells to therapeutic cells.”
A Structural View on Medicinal Chemistry Strategies against Drug Resistance
Agnello, S., Brand, M., Chellat, M. F., Gazzola, S., & Riedl, R. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201802416 · Cited by 74
Prediction of ultra-high-order antibiotic combinations based on pairwise interactions
Katzir, I., Cokol, M., Aldridge, B. B., & Alon, U. S. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006774 · Cited by 77
Vehlow, A., Klapproth, E., Jin, S., Hannen, R., Hauswald, M., Bartsch, J. W., Nimsky, C., Temme, A., Leitinger, B., & Cordes, N. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.096 · Cited by 74
“As intrinsic and acquired resistances to anti-cancer treatment represent universal clinical challenges (Holohan et al., 2013), the unraveling of underlying cellular and microenvironment-driven mechanisms remains of fundamental importance.”
BackgroundGuo, S., Lv, L., Shen, Y., Hu, Z., He, Q., & Chen, X. S. (2016) · Scientific Reports · doi:10.1038/srep21459 · Cited by 71
Yu, J., Qin, B., Moyer, A. M., Sinnwell, J. P., Thompson, K. J., Copland, J. A., Marlow, L. A., Miller, J. L., Yin, P., Gao, B., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0920-8 · Cited by 77
“In breast cancer, as in most solid tumors, intrinsic or acquired drug resistance is a major cause of cancerspecific death [10, 34, 35], Studying the mechanism of drug resistance is greatly hindered by the lack of in vivo models that resemble human cancer biology [25, 34].”
BackgroundSynthesis and in vitro study of modified chitosan-polycaprolactam nanocomplex as delivery system
Rezvani, M., Mohammadnejad, J., Narmani, A., & Bidaki, K. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.02.141 · Cited by 70
“These side effects are originated from large amount usage of chemotherapeutic agents, long-term use and lack of targeting therapy in this approach [6,7].”
BackgroundRahimi, M., Shafiei‐Irannejad, V., Safa, K. D., & Salehi, R. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.05.059 · Cited by 71
Yu, H., Li, J., Deng, K., Zhou, W., Wang, C., Wang, Q., Li, K., Zhao, H., & Huang, S. (2019) · Theranostics · doi:10.7150/thno.35748 · Cited by 69
“Unfortunately, the drug resistance often occurred shortly after chemotherapy in the clinic [1,2].”
BackgroundThe Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment
Fridman, E., Ginini, L., & Gil, Z. (2022) · Cells · doi:10.3390/cells11091433 · Cited by 71
“Chemotherapeutic resistance can be broadly divided into several categories—drug transport and metabolism, alternations in drug targets, and adaptive response (DNA repair) [86].”
BackgroundHe, J., Zhou, Y. L., & Sun, L. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01438-0 · Cited by 84
“Platinum drugs, including cisplatin, carboplatin, and oxaliplatin, can be covalently linked with thiol glutathione, which leads to their inactivation, decreases the availability of the native drug to bind its target, and promotes drug efflux by ABC transporters [130, 150].”
BackgroundMathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy
Gallagher, K., Strobl, M. A. R., Park, D. S., Spoendlin, F. C., Gatenby, R. A., Maini, P. K., & Anderson, A. R. A. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2040 · Cited by 80
Role of circulating tumor cells in future diagnosis and therapy of cancer
Potdar, P. D., & Lotey, N. (2015) · Journal of Cancer Metastasis and Treatment · doi:10.4103/2394-4722.158803 · Cited by 82
“In such cases, continuation of the same treatment only worsens the condition, therefore, there is a need of extremely specifi c and targeted therapy which can help the survival of patients in such situations.[4] It is increasingly becoming a prerequisite to take a “fi ngerprint” of a given tumor and then proceed with…”
BackgroundThree-dimensional bio-printing: A new frontier in oncology research
Charbe, N. B., McCarron, P. A., & Tambuwala, M. M. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i1.21 · Cited by 78
Chakrabarti, S., & Michor, F. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2871 · Cited by 72
“As cancer arises due to a process of somatic Darwinian evolution (1 – 3), researchers have to grapple with the inexor-able reality of development of resistance to anticancer drugs (4 – 6).”
Li, J., Qu, X., Tian, J., Zhang, J., & Cheng, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193318 · Cited by 77
Mogilevsky, M., Tepper, O., Kumar, S., Mogilevsky, A., Keshet, E., Yavin, E., Heyd, F., & Karni, R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky921 · Cited by 69
“Drug resistance of cancer cells is a major roadblock in cancer treatment, specifically for glioblastoma treatment (16).”
BackgroundUkai, S., Honma, R., Sakamoto, N., Yamamoto, Y., Phạm, Q. T., Harada, K., Takashima, T., Taniyama, D., Asai, R., Fukada, K., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01492-9 · Cited by 73
Borah, B. M., Cacaccio, J., Durrani, F. A., Bshara, W., Turowski, S. G., Spernyak, J. A., & Pandey, R. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-78153-0 · Cited by 73
Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models
Kim, E., Brown, J. S., Eroglu, Z., & Anderson, A. R. A. (2021) · Cancers · doi:10.3390/cancers13040823 · Cited by 82
“Several studies have shown that phenotypic switching between sensitive and resistance types provides another avenue for acquired resistance during therapy [8,12,13].”
BackgroundZhang, H., Shi, Y., Liu, J., Wang, H., Wang, P., Wu, Z., Li, L., Gu, L., Cao, P., Wang, G., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15765 · Cited by 70
Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers
Farooqı, A. A., Khalid, S., & Ahmad, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030652 · Cited by 70
“Using high-throughput technologies, it has been shown that the bulk tumor includes a diversified collection of cells that harbor characteristically unique molecular features with variable levels of sensitivity to therapeutic options [1,2].”
BackgroundProdrugs for targeted cancer therapy
Souza, C., Pellosi, D. S., & Tedesco, A. C. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1615890 · Cited by 72
“The induction of multiple drug resistance (MDR) and metastasis are also critical issues associated with chemotherapy [2,6].”
BackgroundPVT1 Long Non-coding RNA in Gastrointestinal Cancer
Martínez‐Barriocanal, Á., Arango, D., & Dopeso, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00038 · Cited by 86
“Intrinsic and acquired resistance to therapeutic agents is the first cause of treatment failure in cancer patients (153).”
BackgroundGuo, F., Cao, Z., Guo, H., & Li, S. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6052 · Cited by 67
“…transition are associated with chemotherapy resistance (9); a common mechanism for obtaining resistance is the energy-dependent translocator expression, accelerated cell excretion of anticancer drugs, induction of drug detoxification and reduced susceptibility to apoptosis signals (10).”
Chen, Z., Wu, L., Zhou, J., Lin, X., Peng, Y., Ge, L., Chiang, C., Huang, H., Wang, H., & He, W. (2020) · Theranostics · doi:10.7150/thno.40144 · Cited by 73
“Chemotherapy using one or more anticancer drugs is the major strategy for cancer treatment, particularly for patients with advanced and/or metastatic tumors that cannot undergo surgery [1].”
BackgroundAltered glycolysis results in drug‑resistant in clinical tumor therapy (Review)
Peng, J., Cui, Y., Xu, S., Wu, X., Huang, Y., Zhou, W., Wang, S., Fu, Z., & Xie, H. (2021) · Oncology Letters · doi:10.3892/ol.2021.12630 · Cited by 84
“The incidence and mortality rates associated with cancer remain high, and despite the vast array of treatments available, chemotherapy resistance remains a significant challenge (4).”
BackgroundDong, X., Sun, Y., Li, Y., Ma, X., Zhang, S., Yuan, Y., Kohn, J., Liu, C., & Qian, J. (2021) · Small · doi:10.1002/smll.202007672 · Cited by 67
Polymer-metal-organic framework hybrids for bioimaging and cancer therapy
Fu, D., Liu, X., Zheng, X., Zhou, M., Wang, W., Su, G., Liu, T., Wang, L., & Xie, Z. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214393 · Cited by 71
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
Application of molecular dynamics simulation in self-assembled cancer nanomedicine
Xu, X., Liu, A., Liu, S., Ma, Y., Zhang, X., Zhang, M., Zhao, J.-H., Sun, S., & Sun, X. J. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00386-7 · Cited by 73
“MD simulation is a reasonable method to self-assemble two or more drugs into nanoparticles for better drug delivery and combined therapy [139, 140].”
MethodOvercoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Koirala, M., & DiPaola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081801 · Cited by 75
“In this review, we outline the various identified modes of drug resistance, which include drug efflux, drug target alterations, DNA repair, cell death inhibition, evasion of drug action, microenvironmental changes, and an epithelial-to-mesenchymal transition (Figure 1) [5].”
BackgroundWang, J., Lu, M. L., Dai, H. L., Zhang, S., Wang, H. X., & Wei, N. (2015) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20144074 · Cited by 73
“Apoptosis is a key processmediated by chemotherapeutic agents and it contributes to efficacy (18).”
BackgroundmiR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD
Zhu, M., Xin Min, Z. H. O. U., Du, Y., Huang, Z., Zhu, J., Xu, J., Cheng, G., Shu, Y., Liu, P., Zhu, W., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5413 · Cited by 67
“In addition, molecular mechanisms, including increased rates of drug efflux, alterations in drug metabolism and mutation of drug targets may be important in drug resistance (4,5).”
BackgroundMicroRNAs are important regulators of drug resistance in colorectal cancer
Zhang, Y., & Wang, J. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0308 · Cited by 69
“In addition, cancer stem cells (CSCs) have been implicated to be Brought to you by | Washington University in St. Louis Authenticated Download Date | 1/19/17 2:04 AM 6 / 21 resistant to chemotherapeutic agents (Holohan et al., 2013).”
BackgroundKamarajan, P., Rajendiran, T. M., Kinchen, J. M., Bermúdez, M., Danciu, T., & Kapila, Y. L. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00936 · Cited by 71
Irace, C., Misso, G., Capuozzo, A., Piccolo, M., Riccardi, C., Luchini, A., Caraglia, M., Paduano, L., Montesarchio, D., & Santamaria, R. (2017) · Scientific Reports · doi:10.1038/srep45236 · Cited by 73
Isgut, M., Mukkavilli, R., Yang, C., Subrahmanyam, V., Rida, P. C. G., & Aneja, R. (2017) · Medicinal Research Reviews · doi:10.1002/med.21444 · Cited by 69
Lucien, F., Pelletier, P.-P., Lavoie, R. R., Lacroix, J.-M., Roy, S., Parent, J.-L., Arsenault, D., Harper, K., & Dubois, C. M. (2017) · Nature Communications · doi:10.1038/ncomms15884 · Cited by 66
“A major challenge in treating cancer is resistance to therapy 1 .”
Alharbi, M. G., Sharma, S., Guanzon, D., Lai, A., Zuñiga, F. A., Shiddiky, M. J. A., Yamauchi, Y., Salas-Burgos, A., He, Y., Pejovic, T. B., et al. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102207 · Cited by 69
Molecular Markers Guiding Thyroid Cancer Management
Nylén, C., Mechera, R., Maréchal-Ross, I., Tsang, V., Chou, A. S. Y., Gill, A. J., Clifton-Bligh, R. J., Robinson, B. G., Sywak, M. S., Sidhu, S. B., et al. (2020) · Cancers · doi:10.3390/cancers12082164 · Cited by 73
“The development of potent preclinical models, high throughput molecular technologies such as next-generation sequencing (NGS) and gene expression microarrays have provided a deeper understanding of genetic alterations and molecular characteristics in cancer [13].”
BackgroundChen, W., Luo, G., Qiu, W., Lei, Q., Liu, L., Zheng, D., Hong, S., Cheng, S., & Zhang, X. (2016) · Chemistry of Materials · doi:10.1021/acs.chemmater.6b03236 · Cited by 66
Ma, K., Xing, R., Jiao, T., Shen, G., Chen, C., Li, J., & Yan, X. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b10754 · Cited by 66
Zeng, Y., Yang, Z., Li, H., Hao, Y., Liu, C., Zhu, L., Liu, J., Lu, B., & Li, R. (2017) · Scientific Reports · doi:10.1038/srep43506 · Cited by 68
Tumor associated macrophages and ‘NO’
Nath, N., & Kashfi, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113899 · Cited by 68
Lelièvre, P., Sancey, L., Coll, J., Deniaud, A., & Busser, B. (2020) · Cancers · doi:10.3390/cancers12123524 · Cited by 78
Jiang, H., Li, A. M., & Ye, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004978 · Cited by 73
Xi, J., Yun, M., Lee, D., Park, M. N., Kim, E., Sohn, E. J., & Kwon, B.-M. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373993 · Cited by 69
Ferreiro, J. F., Rouhi, L., Urbánková, H., van der Krogt, J., Michaux, L., Shetty, S., Krenács, L., Tousseyn, T., Paepe, P. D., Uyttebroeck, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102977 · Cited by 66
“Amplification, rearrangement and/or overexpression of ABCB1 have been associated with chemotherapy failure in many cancers [47–51].”
BackgroundXu, J., Yue, C.-F., Zhou, W.-H., Qian, Y., Zhang, Y., Wang, S.-W., Liu, A.-W., & Liu, Q. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-200 · Cited by 70
“Moreover, recent studies have shown a link between chemotherapy resistance and the EMT phenotype [40-42].”
BackgroundChen, X., & Liu, Z. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb00694a · Cited by 66
Lu, R., Hu, X., Zhou, J., Sun, J., Zhu, A. Z., Xu, X., Zheng, H., Gao, X., Wang, X., Jin, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12044 · Cited by 74
Mitochondria-Targeted Chimeric Peptide for Trinitarian Overcoming of Drug Resistance
Han, K., Zhu, J., Jia, H.-Z., Wang, S., Li, S., Zhang, X., & Han, H. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b06522 · Cited by 68
Hammerlindl, H., & Schaider, H. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0435-1 · Cited by 75
“̂ Unfortunately, responses to targeted therapy are often short lived (Holohan et al. 2013) and immunotherapies as well lead to”
BackgroundRigali, S., Anderssen, S., Naômé, A., & van Wezel, G. P. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.007 · Cited by 66
Harnessing Tumor Evolution to Circumvent Resistance
McNamara, K. L., & Curtis, C. N. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.007 · Cited by 78
“Unfortunately, for many solid tumors, response to targeted therapies is often 50% or lower [4].”
BackgroundInfluentialMarampon, F., Ciccarelli, C., & ZANI, B. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102530 · Cited by 78
“On the other hand, acquired therapy resistance broadly describes the case in which resistance develops during the course of therapy from a population of cells that were initially sensitive [157].”
BackgroundMiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
Xu, W., Hua, Y.-T., Deng, F., Wang, D., Wu, Y. F., Zhang, W., & Tang, J. (2020) · Cancer Science · doi:10.1111/cas.14517 · Cited by 71
Current State of Biomarkers in Ovarian Cancer Prognosis
Au, K. K., Josahkian, J. A., Francis, J., Squire, J. A., & Koti, M. (2015) · Future Oncology · doi:10.2217/fon.15.251 · Cited by 68
Wang, X., He, S., Gu, Y., Wang, Q., Chu, X., Jin, M., Xu, L., Wu, Q., Zhou, Q., Wang, B., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.037 · Cited by 67
“All of these ABC transporters exhibit overlapping substrate specificity and promote the removal of chemotherapeutic compounds, such as taxanes, topoisomerase inhibitors and antimetabolites, from cells [6].”
BackgroundEl‐Naggar, A. M., Eissa, I. H., Belal, A., & El‐Sayed, A. A. (2020) · RSC Advances · doi:10.1039/c9ra10094f · Cited by 69
Circulating tumor cell profiling for precision oncology
Labib, M., & Kelley, S. O. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12901 · Cited by 73
Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer
Wang, W., Jin, Y., Liu, X., Chen, F., Zheng, X., Liu, T., Yang, Y., & Yu, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100386 · Cited by 71
Metadata
- Authors
- Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 714-726
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042619042
- Cited by
- 4,681
- References
- 178
- Citations by year
- 2026: 322 · 2025: 358 · 2024: 327 · 2023: 356 · 2022: 364 · 2021: 442 · 2020: 465 · 2019: 460 · 2018: 433 · 2017: 385 · 2016: 342 · 2015: 276 · 2014: 135 · 2013: 4
- FWCI
- 26.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Cancer Research UK (13172, 13721, C212/A13721)
- Public Health Agency (RRG/3261/05)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- chemoresistance, targeted therapy, drug target alterations, cell death evasion, predictive biomarkers, patient stratification, high-throughput screening, preclinical models
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, Autophagy, Biological Transport, Biotransformation, DNA Damage, DNA Repair, Humans, Models, Biological, Mutation, Neoplasm Proteins, Neoplastic Stem Cells, Drug Design, Gene Expression Regulation, Neoplastic, Apoptosis, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Gene Silencing, Apoptosis Regulatory Proteins, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.